Improvement from baseline scores in SPARCC (SI joints) and Berlin (spine) at weeks 48 and 96 of the RAPID-axSpA trial for all patients in the imaging set (observed data)
| All CZP (dose combined) | ||||
|---|---|---|---|---|
| N | Mean score at baseline (SD)* | Mean score (SD) | Mean change from baseline (SD) | |
| SPARCC (SI joints) | ||||
| Week 48 | ||||
| axSpA | 113 | 9.0 (13.3) | 2.7 (5.7) | −6.3 (12.7) |
| r-axSpA | 61 | 9.6 (14.9) | 2.0 (4.5) | −7.6 (13.0) |
| nr-axSpA | 52 | 8.3 (11.3) | 3.5 (6.9) | −4.8 (12.2) |
| Week 96 | ||||
| axSpA | 125 | 9.2 (13.1) | 2.1 (6.2) | −7.2 (12.6) |
| r-axSpA | 77 | 9.5 (14.1) | 1.4 (5.6) | −8.1 (12.7) |
| nr-axSpA | 48 | 8.8 (11.4) | 3.2 (7.0) | −5.6 (12.4) |
| Berlin (spine) | ||||
| Week 48 | ||||
| axSpA | 114 | 3.8 (5.7) | 1.4 (2.6) | −2.4 (4.4) |
| r-axSpA | 62 | 4.6 (5.6) | 1.7 (3.2) | −2.9 (4.0) |
| nr-axSpA | 52 | 2.9 (5.7) | 1.0 (1.5) | −1.9 (4.7) |
| Week 96 | ||||
| axSpA | 126 | 4.7 (6.2) | 1.4 (2.5) | −3.3 (5.1) |
| r-axSpA | 78 | 5.6 (6.3) | 1.6 (2.9) | −4.0 (5.1) |
| nr-axSpA | 48 | 3.3 (5.9) | 1.0 (1.7) | −2.3 (5.0) |
Patients randomised to placebo at baseline received CZP from week 16 (if escaping early), or week 24 (if completing double-blind phase) and are included in weeks 48 and 96 results.
*Matched baseline readings; in the week 96 reading campaign, MRIs from each previous visit were re-read.
axSpA, axial spondyloarthritis; CZP, certolizumab pegol; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada.